Maxcyte (MXCT) Equity Average (2020 - 2026)

Maxcyte (MXCT) has 7 years of Equity Average data on file, last reported at $169.7 million in Q1 2026.

• Equity Average for Q1 2026 came in at $169.7 million, down 16.34% year-over-year; the trailing twelve-month figure through Mar 2026 was $169.7 million (down 16.34% YoY), and the FY2025 annual result was $188.9 million, down 13.84% from the prior year.
• Equity Average retreated to $169.7 million in Q1 2026 per MXCT's latest filing, from $175.9 million in the prior quarter.
• Over five years, Equity Average peaked at $262.5 million in Q1 2022 and troughed at $169.7 million in Q1 2026.
• A 5-year average of $223.9 million and a median of $229.3 million in 2024 frame the typical range for Equity Average.
• The sharpest annual moves came in 2022 and 2026: Equity Average jumped 358.54% in 2022, then declined 16.34% in 2026.
• A 5-year view of Equity Average shows it stood at $254.2 million in 2022, then fell by 8.43% to $232.8 million in 2023, then retreated by 9.88% to $209.8 million in 2024, then retreated by 16.16% to $175.9 million in 2025, then retreated by 3.52% to $169.7 million in 2026.
• Business Quant data shows MXCT's Equity Average at $169.7 million in Q1 2026, $175.9 million in Q4 2025, and $185.5 million in Q3 2025.